Skip to main content
Indiana University School of Medicine
Indiana University School of Medicine
Department of Medicine
Physician-scientists at IU School of Medicine conduct ground-breaking liver research to understand primary biliary cholangitis (PBC).

Primary Biliary Cholangitis

Primary biliary cholangitis (PBC), previously called primary biliary cirrhosis, is a chronic disease in which the bile ducts in the liver are slowly destroyed.

Investigators

4796-Lammert, Craig Craig Lammert, MD

Craig Lammert, MD

Associate Professor of Medicine

5034-Vuppalanchi, Raj Raj Vuppalanchi, M.D.

Raj Vuppalanchi, M.D.

Professor of Medicine

Open Research Studies for Primary Biliary Cholangitis

Zydus PBC

Enrolling: Yes

Principle Investigator: Raj Vuppalanchi, MD

Duration: 26 weeks

Patient Population: Non-cirrhotic

Drug(s): Oral Saroglitazar

Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects with Primary Biliary Cholangitis

Enrolling: Yes

Principle Investigator: Raj Vuppalanchi, MD

Duration: 59 weeks

Patient Population: Patients diagnosed with PBC

Drug(s): Saroglitazar Magnesium

Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu

View the study on clinicaltrials.gov

Closed Primary Biliary Cholangitis Studies

Enrolling: No

Principle Investigator: Raj Vuppalanchi, MD

Duration: Upwards 6 - 8 years.

Patient Population: PBC with total Bili > ULN and ≤3x ULN or ALP >5x ULN

Drug(s): Obeticholic Acid tablet or placebo

Enrolling: No

Principle Investigator: Craig Lammert, MD

Duration: 1 visit

Patient Population: PBC/Pre-Transplant and history of no/minimal itch or severe itch.

Enrolling: No

Principle Investigator: Raj Vuppalanchi, MD

Duration: 21 weeks

Patient Population: Patients with moderate to severe itching.

Drug(s): Oral CR845

Clinicaltrials.gov